Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company ...

Completed the acquisition of Ambry Genetics on February 3, 2025. Announced the national launch of the Company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx which was granted ADLT ...

All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash payments and $225 million in shares. Plus, Nancy Pelosi ...

Linh H. Le is an accomplished finance and accounting executive with extensive knowledge and expertise that he has implemented ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

The company recently acquired genetic testing pioneer Ambry Genetics in a strategic move to utilize its diagnostics and data to fuel innovation and enhance solutions for patients, clinicians ...

Tempus AI expects full-year 2025 revenue of approximately $1.24 billion for its consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth. Analysts are ...

Adjusted EBITDA for 2025: Expected to be approximately $5 million. Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years.